gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
gptkbp:activities
|
depletes B cells
|
gptkbp:appointed_by
|
intravenous infusion
|
gptkbp:approves
|
gptkb:1997
gptkb:2006
gptkb:FDA
|
gptkbp:associated_with
|
gptkb:granulomatosis_with_polyangiitis
gptkb:microscopic_polyangiitis
gptkb:healthcare_organization
gptkb:psychologist
B-cell malignancies
B-cell autoimmune disorders
|
gptkbp:brand
|
gptkb:Rituxan
|
gptkbp:can_be_used_with
|
gptkb:methotrexate
|
gptkbp:clinical_trial
|
gptkb:Rituximab_biosimilars
oncology
hematology
rheumatology
Phase III
|
gptkbp:contraindication
|
active infections
severe allergic reactions
history of severe allergic reactions
severe immunosuppression
|
gptkbp:developed_by
|
gptkb:Genentech
|
gptkbp:discovered_by
|
1990s
|
gptkbp:dosage_form
|
gptkb:software_framework
|
gptkbp:duration
|
varies
|
gptkbp:financial_performance
|
24 months
|
gptkbp:first_introduced
|
gptkb:1997
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rituximab
|
gptkbp:indication
|
gptkb:granulomatosis_with_polyangiitis
gptkb:microscopic_polyangiitis
autoimmune diseases
|
gptkbp:influenced_by
|
monoclonal antibody technology
|
gptkbp:influences
|
inflammatory response
immune system
autoimmune response
|
gptkbp:ingredients
|
C6420 H9920 N1710 O1980 S44
C6428 H9924 N1716 O1984 S46
|
gptkbp:interacts_with
|
live vaccines
other biologics
immunosuppressive drugs
|
gptkbp:invention
|
gptkb:2016
|
gptkbp:is_available_on
|
gptkb:physicist
generic version
|
gptkbp:is_monitored_by
|
infusion reactions
blood cell counts
blood counts
infection signs
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
gptkb:Non-Hodgkin_lymphoma
gptkb:non-Hodgkin_lymphoma
gptkb:rheumatoid_arthritis
gptkb:Chronic_lymphocytic_leukemia
treatment of rheumatoid arthritis
treatment of chronic lymphocytic leukemia
treatment of non-Hodgkin lymphoma
|
gptkbp:manager
|
IV
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
multiple countries
|
gptkbp:price
|
varies by region
|
gptkbp:produced_by
|
gptkb:Genentech
Chinese hamster ovary cells
|
gptkbp:research
|
gptkb:musician
gptkb:healthcare_organization
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:Sjogren's_syndrome
gptkb:psychologist
gptkb:Insurance_Company
gptkb:motorcycle
gptkb:computer
gptkb:systemic_sclerosis
gptkb:dermatomyositis
gptkb:sarcoidosis
clinical trials
fibromyalgia
psoriasis
anemia of chronic disease
combination therapies
biomarker studies
other autoimmune diseases
transplantation
thrombotic thrombocytopenic purpura
long-term effects studies
pharmacokinetics studies
chronic urticaria
hemophagocytic lymphohistiocytosis
chronic pain syndromes
idiopathic thrombocytopenic purpura
adult-onset Still's disease
pediatric autoimmune diseases
relapsing polychondritis
|
gptkbp:research_focus
|
cancer immunotherapy
autoimmune disease treatment
B-cell depletion therapy
|
gptkbp:shelf_life
|
24 months
|
gptkbp:side_effect
|
gptkb:progressive_multifocal_leukoencephalopathy
fatigue
headache
nausea
fever
neurological symptoms
cardiovascular events
skin reactions
infections
increased risk of infections
hypotension
infusion reactions
hypersensitivity reactions
gastrointestinal symptoms
pulmonary toxicity
tumor lysis syndrome
|
gptkbp:storage
|
refrigerated
|
gptkbp:suitable_for
|
pregnant women
breastfeeding women
|
gptkbp:targets
|
C D20 protein
|
gptkbp:traded_on
|
gptkb:Rituxan
|
gptkbp:website
|
IV site
|
gptkbp:weight
|
143 k Da
|
gptkbp:bfsParent
|
gptkb:Biogen_Inc.
gptkb:Biogen
gptkb:Rituxan
|
gptkbp:bfsLayer
|
4
|